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Abstract
This paper aims to systematically review the cost-effectiveness evidence, and to provide a critical appraisal of the
methods used in the model-based economic evaluation of CRC screening and subsequent surveillance. A search
strategy was developed to capture relevant evidence published 1999-November 2012. Databases searched were
MEDLINE, EMBASE, National Health Service Economic Evaluation (NHS EED), EconLit, and HTA. Full economic
evaluations that considered costs and health outcomes of relevant intervention were included. Sixty-eight studies
which used either cohort simulation or individual-level simulation were included. Follow-up strategies were mostly
embedded in the screening model. Approximately 195 comparisons were made across different modalities;
however, strategies modelled were often simplified due to insufficient evidence and comparators chosen
insufficiently reflected current practice/recommendations. Studies used up-to-date evidence on the diagnostic test
performance combined with outdated information on CRC treatments. Quality of life relating to follow-up
surveillance is rare. Quality of life relating to CRC disease states was largely taken from a single study. Some studies
omitted to say how identified adenomas or CRC were managed. Besides deterministic sensitivity analysis,
probabilistic sensitivity analysis (PSA) was undertaken in some studies, but the distributions used for PSA were rarely
reported or justified. The cost-effectiveness of follow-up strategies among people with confirmed adenomas are
warranted in aiding evidence-informed decision making in response to the rapidly evolving technologies and rising
expectations.
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Introduction
Colorectal polyps are small benign growths in the inner
layer of the colon and rectum that can be either
pre-cancerous or non-precancerous. Neoplastic colorectal
polyps, known as adenomas, can be further divided into
non-advanced and advanced dependent on the size,
degree of villous features, or grade of dysplasia [1,2]. The
number and size of adenomas are positively related to the
risk of developing colorectal cancer (CRC) over 10 years
or longer [1,3,4]. Evidence suggests that early detection
and removal of colorectal adenomas (polypectomy) reduces
the risk of developing CRC [4].
Several screening modalities are currently used in differ-
ent sequences and with different intervals ranging from
stool tests, barium enema (BE), colonoscopy (COL),
sigmoidoscopy (SIG) to computerised tomography
colonography (CTC). Each screening modality has particu-
lar benefits and potential harms. Despite the absence of suf-
ficient evidence for or against specific CRC screening
modalities, CRC screening has been implemented in many
countries [5–7]. Rapidly evolving technologies and increas-
ing expectations from healthcare users tend to exceed fi-
nancial affordability and health policy responses in many
countries. Guidance is required regarding choice and order
of modalities, and appropriate intervals, in order to minim-
ise potential harms and maximise benefits among the eli-
gible population groups. This paper systematically reviews
the cost-effectiveness evidence and provides a critical ap-
praisal of methods used in the model-based economic
evaluation of CRC screening and subsequent surveillance.
Review
Methods
A search strategy was developed (Additional file 1).
Databases searched were National Health Service Economic
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Evaluation Database (NHS EED), EconLit, MEDLINE,
EMBASE, and HTA and limited to studies published
January 1999 to November 2012. An initial search using
the search term ‘surveillance’ was extended to ‘screening’
because of the rarity of published cost-effectiveness
analysis of follow-up strategies in the topic area, and
also due to terminologies being used interchangeably in
the published literature. Key terms used in the search were
colonoscopy, surveillance, screening, adenoma, colorectal
cancer. Economic filters were used when searching for
economic evidence on generalist databases, such as
MEDLINE. Simplified searches without economic search
filters were performed when searching the economics
specific databases [8].
Full economic evaluations that considered costs and
health outcomes of relevant types of intervention with out-
comes expressed in cost per quality-adjusted life-year
(QALY); or cost per life-year gained were included. Studies
published pre-1999 [9,10] were reviewed when they were
used in the appraisal of newly introduced technologies.
Sixty-eight studies were critically appraised by two
reviewers using a set of criteria [11]. Further details are
described in additional file 2 and additional file 3, and the
included studies are summarised in additional file 4.
Findings from selected studies are discussed in the
following section.
Findings
Economic models for surveillance programmes targeting
people with a high risk of developing CRC were nested in
the main screening model(s) in a number of occasions.
The country of origin of the included studies is presented
in Figure 1.
Modelling methods
Two modelling methods have been used; cohort simulation
and individual-level simulation. Some studies provided
a limited description of the model [9,12–15], others
were marginal analyses of cost and benefits derived
from published studies that were applied directly to the
US population [16].
Computational complexity of the models ranged from a
simple decision tree [17–24] to a Markov model [10,25–57]
to capture key aspects of natural history of CRC. Most
studies modelled the adenoma-carcinoma sequence over
time. Threshold analysis was performed in some studies to
investigate the optimal cut-off level for diagnostic tests or
optimal reimbursement strategy for a new technology [58].
Individual-level simulation models [58–69] have been
based on three micro simulation models: Micro Simula-
tion Screening Analysis (MISCAN), Simulated Model of
Colorectal Cancer (SimCRC), and the Colorectal Cancer
Simulated Population model for Incidence and Natural
History (CRC-SPIN). These were independently developed
within the National Cancer Institute-funded Cancer Inter-
vention and Surveillance modelling Network (CISNET)
consortium. The natural history of CRC in these models
was calibrated to autopsy studies and to Surveillance,
Epidemiology, and End Results (SEER) Program data for the
pre-screening era (1975–1979) [60]. CISNET models subse-
quently led to a number of secondary analyses [36,66–69].
Initiation of CRC screening and subsequent follow-up
was mostly around 50 to 60 years of age, while the
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Figure 1 Included studies.
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timing of cessation of screening or surveillance varied.
In some surveillance models, people remained in the
surveillance programme until the end of the simulation
[60,66]. As a result, the surveillance costs would have been
overestimated.
Population considered
People at average risk were the main focus in most studies,
with follow-up surveillance nested in the screening model.
For people with positive FOBT results COL was commonly
used as a confirmatory test [21,53,68,70]. The importance
of follow-up surveillance of individuals at high risk of
developing CRC has been recognised in recent years.
For example, people with newly diagnosed adenomas were
considered in a follow-up strategy using COL compared
with no follow-up [44], and people with asymptomatic
polyps were followed-up using CTC compared with
immediate referral for COL with polypectomy [22,23].
Screening modalities considered
The main interventions chosen for modelling were stool
tests, COL, SIG progressed to CTC either alone or com-
bined with another modality. CTC was often compared
with existing technologies that have emerged in the recent
years. Evidence and recommendations on the use of BE
remain inconsistent thus BE was considered as one of the
current modalities in some studies [20,27,51,56] but
excluded in others [47,52].
Stool-based tests, including guiaic FOBT (gFOBT),
immunochemical FOBT (iFOBT) and stool DNA tests,
were used for mass screening of those at average risk of de-
veloping CRC compared with no screening [38,51,71,72].
COL was the common test for the follow-up of detected
adenomas/polyps and positive test results from initial
screening tests. Unlike COL, SIG provides visualised
examination of the left side of the bowel depending on the
length of endoscopy and the depth of insertion with no
sedation [73]. Narrow-band imaging (NBI) is one of latest
technologies with in-vivo histology function compared with
conventional white light COL, in which removed adenomas
from COL (polypectomy) would be analysed in the lab [29].
Approximately 195 comparisons have been made across
the 68 studies (simplifying considerations of the sequence
of tests and excluding the interval of screening and fol-
low-up strategies) (Figure 2). This can be partly explained
by differences in clinical practice between countries/settings
dependent on the structure of health service delivery and
reimbursement rules, as well as resource availability.
Effectiveness and cost-effectiveness evidence relating to
the combination of different tests or their sequence in
CRC screening and follow-up was sparse. Stool-based
tests were aggregated for simplicity. Each modality is
coded using a different colour and shape outline. Numbers
shared between circles or within a circle represent the
number of comparisons across the studies. For example,
NBI was compared with COL once; two comparisons
were made of CTC followed by COL and CTC alone.
Threshold analyses at various costs and sensitivity of
CTC in detecting polyps were presented in comparison
with existing modalities among an average risk population
[59,66,69]. Some studies found CTC, with or without a
threshold strategy for the size of polyps, would be
cost-effective, while others found COL or iFOBT to be
cost-effective. This depended on where CTC was used in
the screening pathway either primary screening or
secondary follow-up test. Cost-effectiveness of CTC was
examined in recent years with an improved understanding
of the test performance and indications among people
with asymptomatic polyps or with a positive result from
FOBT [21–23]. A definitive follow-up interval using
CTC has not been empirically established, thus modelled
intervals of CTC strategy varied from every 5 years to
10 years among average risk population, or every 3 years
among asymptomatic people with small polyps (6–9 mm)
[26,37,49,55].
The potential harm of CTC was rarely considered,
although exposure to radiation from CTC every 3 or
5 years was reported to be low [49]. CTC was considered
as a primary screening test in an average population
compared with FOBT [25], COL [49], SIG [34,60,69].
No studies have considered the costs and consequences
of extra colonic findings from CTC.
CTC was not cost-effective as a follow-up test for indi-
viduals with positive results from stool tests when com-
pared with COL [24,55]. CTC was relatively cost-effective
or cost-saving among people with polyps 6–9 mm [22,23]
(Table 1).
The frequency and interval of modelled strategies were
restricted and simplified compared with day-to-day clinical
practice and current guidance/recommendations. This
could misrepresent the cost-effectiveness of CTC and
other screening modalities [74].
Management of polyps/adenomas and CRC
Follow-up was modelled for those with positive results
from stool-based tests or polyps detected using endoscopy-
based tests or image-based tests. For confirmed polyps,
the interval and the degree of complexity of follow-up
strategies varied greatly from simple COL at 3–10 years
after initial polypectomy to multiple strategies based on
the current recommended guidelines [9,57,75]. Follow-up
was nested within a Markov model [20,32,38,39] or a
discrete event simulation [25,65], or not modelled [37].
Crudely simplified follow-up strategies were considered
with assumptions that departed from the real-world,
for example, 100% compliance or a common compliance
rate at any screening round [9,22,58,61,62]. Cost-effective-
ness was generally recognised to depend on compliance
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with screening, however, one study suggested that
high compliance rates were not necessary to achieve
cost-effectiveness [19].
Detected polyps were grouped into a single state or
two or three depending on number and size of polyps
found at baseline COL [30,42,65,76]. Modelled disease
states of CRC were mainly local, regional or distant
(disseminated) (CRC or Dukes’ stages A to D). In some
studies a single CRC disease state was used with an
average lifetime treatment cost predicted or estimated
thus the results failed to predict benefits of early detection
and prevention of CRC [14,19,50]. More recently the costs
of CRC stage-specific treatment were modelled including
combination and/or sequence of treatments [26,52,70,75].
Costs of CRC treatment were not stated, or were crudely
simplified as lifetime costs [50], or directly lifted from
previous publications without adjusting to the current
year [17,42]. Given the primary goal of screening is
prevention and early detection of disease, it is crucial to
capture not only the initial years of screening [71] but
also the longer term benefits accrued over a lifetime. Any
differences in the CRC treatment costs as a result of
prevention or early detection of CRC were not distinguished
in the model.
Input parameters
Since direct evidence on the natural history of CRC is
lacking, input parameters were taken from multiple sources
ranging from epidemiological studies, hospital records,
disease registries and expert opinion.
Papers emphasised the improved test performance of
their chosen modalities (and their effectiveness and cost-
effectiveness) but often combined more recent information
on test performance with existing, outdated information on
resource use. For example, the cost-effectiveness of CRC
screening with CTC was presented using a single CRC
treatment cost taken from a previous study [48] and costs
per test from 1998 [42]. COL related complications were
modelled in terms of costs. Test performance of CTC
varied in the studies from 33% to 100% depending on
the size of polyp [22,23,42] (Table 1). In the absence of
sensitivity and specificity data for new technologies test
performance similar to existing tests was assumed [49].
Quality of life relating to CRC was repeatedly taken
from a single study [76] for over a decade [26,45,65,75].
More recently, EQ-5D values of cancer-free and cancer
states have been estimated from a national survey [70].
Handling uncertainties and model validation
Key assumptions were mainly examined using deterministic
sensitivity analyses of the adenoma-carcinoma sequence,
CRC prevalence rate, test performance, and compliance
rate. In addition, threshold analyses, and scenario analyses
were performed to address different types of uncertainty
[59,66,69]. However, test performance of screening modal-
ities was not subject to sensitivity analysis in some studies
[27,77]. Sensitivity analyses in most cases confirmed the
base case finding. Besides uncertainty from sampling vari-
ation in the general population, synthesising evidence from
multiple sources in order to estimate cost-effectiveness
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Figure 2 At a glance. Barium enema (BE) (brown solid) and colonoscopy (BE + COL) (brown dotted), Capsule endoscopy (CapEndo) (green
solid), Computerised-tomography colonography (CTC) (grey solid), Computerised-tomography colonography followed by colonoscopy
(CTC→COL), Colonoscopy (COL) (red solid), Narrow-band imaging (NBI) (purple dotted), No intervention (black solid). Sigmoidoscopy (SIG)
(turquoise solid). Sigmoidoscopy combined with barium enema (SIG + BE) (olive green dashed). Stool tests (blue solid). Stool tests combined with
BE (stool tests + BE) (brown solide). Stool tests combined with COL (stool tests + COL) (red dotted), Stool tests combined with SIG (stool tests +
SIG) (turquoise dotted), ‘+’ combination of tests,‘→’ sequence of test.
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Table 1 CTC as a follow-up test
Population Interventions Sensitivity (Se,%) Specificity
(Sp,%) [ranges]
Participation rate: initial
(I) repeated (R) [Ranges
assessed in sensitivity
analysis]
Reported outcomes
Pickhardt (2007) People with small polyps
(6–9 mm) detected at CTC
screening
CTC with or without polyp
size reporting threshold
(6-mm) vs COL + polypectomy
FSIG No screening
(<=5 mm polyps,6-9 mm, > = 10 mm,
CRC) CTC Se (48%, 70%, 85%, 95%)
Sp 86% COL Se(80%, 85%, 90%, 95%)
Sp 90% FSIG (45%, 45%, 60-65%, 90%)
I 65% [1–100] R 80% [1–100] Compared with No screening; $4361per
LYG (CTC with a 6-mm threshold),
$7138 per LYG (CTC with no threshold),
$7407 per LYG (FSIG), $9180 per
LYG (COL).
Compared with COL, CTC with a 6-mm
threshold resulted in a 77.6% reduction
in invasive endoscopic procedures and
1112 fewer reported COL-related
complications from perforation
or bleeding.
CTC with non-reporting of diminutive
lesions was found to be the most
cost-effective and safest screening
option evaluated.
Pickhardt (2008a) 60 years old asymptomatic
polyps; diminutive (≤5 mm),
small (6-9 mm), large (≥10 mm)
CTC then COL with
polypectomy vs CTC only
polyps (≤5 mm, ≥6 mm, ≥10 mm,)
CTC Se (48%, 89%, 94%) CTC
Sp (80%, 8%, 96%)
100% (assumption) Estimated 10Y CRC risk for unresected
diminutive (0.08%), small (0.7%) and
large polyps (15.7%). ICER of removing
all diminutive polyps was $465,407/LYG,
and small CTC-detected polyps $59,015
per LYG. Polypectomy for large
CTC-detected polyps yielded a
cost-saving of $151 per person
screened.
Pickhardt (2008b) 60 years old asymptomatic
individuals with small polyps
(6- to 9-mm) detected at CTC
screening
3-yearly CTC surveillance
vs Immediate polypectomy
CTC Se( polyps 6-9 mm) 89%, Sp
80% COL Se( 6-9 mm polyps) 85%,
Sp 100%
Not stated Without any intervention, the estimated
5-year CRC death rate from 6- to 9-mm
polyps in this concentrated cohort was
0.08%, which is a sevenfold decrease
over the 0.56% CRC risk for the general
unselected screening population. The
death rate was further reduced to 0.03%
with the CTC surveillance strategy and
to 0.02% with immediate colonoscopy
referral. However, for each additional
cancer-related death prevented with
immediate polypectomy versus CTC
follow-up, 9,977 COL referrals would
be needed, resulting in 10 additional
perforations and an incremental CE
ratio of $372,853.
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Table 1 CTC as a follow-up test (Continued)
Walleser (2007) Individuals with a positive
FOBT
CTC vs COL Se,% (CRC-polyps ≥10 mm - polyps
6-9 mm) CTC Se (89 [70–98]-63
[59–85] - 51 [41–60]) Sp CTC
lesions ≥6 mm 90% [88–92] COL
Se (96[80–100]-95[90–98]-99[95–100])
Sp COL lesions ≥6 mm 99.6[99.2-100]
Not stated Australian dollars/LYG
CTC is less effective and more costly
than COL; if CTC was more sensitive
than COL, CTC was more effective, at
higher cost.
COL (colonoscopy); CRC (colorectal cancer); CTC (computerised tomography colonography); FOBT (fecal occult blood test); FSIG (flexible sigmoidocsopy); LYG (life-years gained).
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adds another layer of uncertainty. Probabilistic sensitivity
analysis (PSA) was performed considering the uncertainty
surrounding all parameters simultaneously [13,33,44,55,65]
complementing the deterministic sensitivity analyses.
The distributions used for PSA were reported in only
two studies, although no justification was given for
choosing these distributions [25,45]. Uncertainties sur-
rounding input parameters were addressed using appro-
priate types of sensitivity analyses in some studies, thus
improving credibility and robustness of the reported
results. For example, a number of scenario analyses were
considered in which different adherence rates and lower
subsequent adherence rates were applied across strategies
[75]. Results were sensitive to costs, but sometimes cost
data were not considered in sensitivity analyses [42].
Other studies did not address limitations related to their
assumptions [12,15,56]. Methods for economic evaluation
have been consolidated further over time, and authors
have accordingly explored uncertainty to a greater extent
in recent publications.
Validation of models is desirable in order to minimise
errors and improve study credibility, and consistency
with methodological guides [78]. Model results were not
validated in early publications because no data set was
available [10,61,62]. An extensive ‘debudding exercise’ and
the review of model structure by independent clinicians
were reported as internal validation [75]. Validation of
models was performed by comparing model simulation
results with actual data sets [17,28,40,42–44,54,77] or by
calibration against published studies [32,39,59].
Validation results showed overestimated efficacy for
polypectomy [29], underestimated prevalence of adenoma
compared with an existing study [37], or significantly
different CRC incidence compared with a recent publi-
cation [23], slightly underestimated CRC mortality
compared with existing studies [45], or model’s prediction
of CRC incidence reduction was consistent with available
data [47].
Discussion
Evidence on the natural history of CRC is limited. The
studies identified were predominantly model-based
economic evaluations; because no single trial could
provide the large sample and long-term follow-up data
required to compare screening strategies with differing
screening intervals, and sequences/combinations of tests.
The assumed constant risks of individuals developing
CRC would have under- or over-estimated CRC incidence
and subsequent resource use for its treatment.
In clinical practice, a sequence of the same or different
tests is performed in CRC screening. Compared to current
practice, the modalities modelled were limited and the
adenoma-carcinoma sequence was crudely simplified. As
a consequence of rapidly evolving technology and the
quite poor evidence base regarding natural history, costs,
and health outcomes, many evaluations have been of
limited value in informing routine clinical practice.
It is vital to know which test(s) should be considered
first in which population, or in what combination or
sequence, in order to maximise health benefit considering
best available effectiveness and cost-effectiveness evidence
in the prevention and early detection of CRC. For example,
CTC appeared to be cost-ineffective as a primary screening
modality compared with other tests among average risk
population, but potentially could be cost-effective when
used as a follow-up test in a selected population in a path-
way. A pathway for CRC including screening, follow-up
surveillance and treatment for CRC would provide a
bigger picture compared with studies that provide a
snapshot view [79]. Given the computational complexity
and additional data required for a pathway model, a bal-
ance must be struck between transparency and flexibility
when choosing the modelling approach in each context.
The studies often omitted to say (or simplified) how
identified adenomas or CRC were to be managed or
treated. CRC screening and follow-up tests aim to detect
early CRC or prevent CRC, thus the consequent costs and
health benefits should be accounted for in the model. The
improved test performance of newer modalities was
captured, but their downstream effects for screening/
follow-up were dated. Current or existing guidance on the
cost-effectiveness analysis of CRC treatments should be
linked to the diagnostic tests when estimating cost-
effectiveness of CRC screening and follow-up strategies.
This is because the cost-effectiveness of a diagnostic
strategy depends in part on the consequences for subse-
quent treatment. Furthermore, for the cost-effectiveness
of a new treatment evidence tends to be generated through
randomised clinical trials. However, input parameters for
quality of life have suffered from selection bias because
searches for data have not been conducted as systematic-
ally, and values generally have come from observational
studies. Efforts should be made to have up-to-date input
parameters for down-stream effects in order to estimate
cost-effectiveness of new modalities with less bias and
uncertainty.
Test performance and compliance rates will vary between
screening round and subsequent follow-up testing. Such
variations were crudely simplified by assuming a fixed test
performance and a constant compliance rate, and were
explored in a deterministic sensitivity analysis in most
studies. Further studies varying test performance and
compliance rates at each screening round dependent on
different tests are recommended.
Extra colonic findings from CTC will influence average
screening costs and the subsequent health outcomes, and
therefore should be considered in order to estimate the
relevant costs and health outcomes of CTC strategies.
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The time period during which the cancer is asymptom-
atic but detectable by the screening test or the time by
which the CRC was diagnosed through screening were
insufficiently modelled and explored in sensitivity analyses.
Assumptions are necessary when constructing a model
and uncertainties are introduced at various stages, for
example, multiple sources of key parameters to populate
the model (parameter uncertainty), and the choice of
health states (structural uncertainty). Sensitivity analyses
of carefully chosen aspects of uncertainties can increase
confidence in or question results. Due to the limited evi-
dence on the natural history of the adenoma-carcinoma
sequence, key assumptions are required, however, the
subsequent structural uncertainty was not fully explored
in most studies. Alternative choices of health states or
care pathways should be explored using different scenario
analyses. Parameter uncertainty was not fully explored,
although uncertainties around mean health and mean cost
were explored to a degree. Cost data were rarely explored
in PSA, and when they were the distributions were poorly
justified.
Cost-effectiveness of follow-up strategies and the inter-re-
lation between CRC screening and follow-up programmes
need further study. In addition, other factors, such as
healthcare financing and delivery of health service, should
also be considered because a modality can be cost-effective
in a specific setting, however, this does not guarantee
cost-effectiveness in a different setting.
CRC screening and follow-up tests can be invasive
with unintended consequences, such as perforation and
bleeding, and also involve pre-procedural preparation
and post-procedure rest. These impacts on quality of life,
have been under-studied and under-reported in most
studies. Quality of life data in relation to CRC and colo-
rectal adenoma are very limited, and for over a decade
were largely based on a single study [80]. It is imperative
to establish a better understanding of the impact on
quality of life of CRC screening and follow-up in people
with adenomas and CRC.
Conclusion
Despite many cost-effectiveness analyses having been
published important aspects remains under-researched,
including the consideration of downstream effects (such as
management of adenoma and CRC) linked to appropriate
screening or follow-up tests. It is important to assess the
cost-effectiveness of different combinations or sequences
of follow-up strategies for those with positive results and
identified adenomas from mass screening. Information
generated will serve as a key link between a mass CRC
screening programme and the most appropriate follow-up
tests and relevant treatments, and will also aid decision
makers to introduce appropriate guidance/policy, and
will guide clinical practitioners as to clinically effective
and cost-effective follow-up strategies to offer appropri-
ate individuals. Therefore, cost-effectiveness analysis of
follow-up tests for people with confirmed adenomas is
warranted.
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